Cargando…
N-acetylcysteine (NAC) in schizophrenia resistant to clozapine: a double blind randomised placebo controlled trial targeting negative symptoms
BACKGROUND: Clozapine is an effective treatment for a proportion of people with schizophrenia (SZ) who are resistant to the beneficial effects of other antipsychotic drugs. However, anything from 40–60 % of people on clozapine experience residual symptoms even on adequate doses of the medication, an...
Autores principales: | Rossell, Susan L., Francis, Paul S., Galletly, Cherrie, Harris, Anthony, Siskind, Dan, Berk, Michael, Bozaoglu, Kiymet, Dark, Frances, Dean, Olivia, Liu, Dennis, Meyer, Denny, Neill, Erica, Phillipou, Andrea, Sarris, Jerome, Castle, David J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5024434/ https://www.ncbi.nlm.nih.gov/pubmed/27629871 http://dx.doi.org/10.1186/s12888-016-1030-3 |
Ejemplares similares
-
N-Acetylcysteine (NAC) in Schizophrenia Resistant to Clozapine: A Double-Blind, Randomized, Placebo-Controlled Trial Targeting Negative Symptoms
por: Neill, Erica, et al.
Publicado: (2022) -
M99. INVESTIGATING THE BEST PREDICTIVE CLINICAL FEATURES OF ANTI-N-METHYL-D-ASPARTATE RECEPTOR (NMDAR) ENCEPHALITIS IN THE 2010 AUSTRALIAN NATIONAL SURVEY OF HIGH IMPACT PSYCHOSIS (SHIP) COHORT
por: Rossell, Susan, et al.
Publicado: (2020) -
N-acetylcysteine (NAC) for methamphetamine dependence: A randomised controlled trial
por: McKetin, Rebecca, et al.
Publicado: (2021) -
A randomised controlled trial of a mitochondrial therapeutic target for bipolar depression: mitochondrial agents, N-acetylcysteine, and placebo
por: Berk, Michael, et al.
Publicado: (2019) -
The Multifaceted Therapeutic Role of N-Acetylcysteine (NAC) in Disorders Characterized by Oxidative Stress
por: Raghu, Ganesh, et al.
Publicado: (2021)